

Vermont New Product Launch Report

NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE
81140010110	RoxyBond 5MG	7/1/2022
81140010210	RoxyBond 15MG	7/1/2022
81140010310	RoxyBond 30MG	7/1/2022

10 or 11 Digit NDC

This will include: Drug Trade Name, Active Ingredient, Strength, and Size

Date Product was commercially available

Key **Used for Full Report Due 30 Days After Initial Notice**

Submissions Made To AGO.highcostprescriptiondrugs@vermont.gov

WAC AT INTRODUCTION	MARKETING PRICING PLAN	MARKETING PRICING NONPUBLIC
1093	Our marketing plan is to use Sales Representatives to engage doctors on the appropriate use and benefits of Roxybond. In pricing this NDC, we considered cost of goods to manufacture, research investment costs, medical and patient service costs.	Y
1323	Our marketing plan is to use Sales Representatives to engage doctors on the appropriate use and benefits of Roxybond. In pricing this NDC, we considered cost of goods to manufacture, research investment costs, medical and patient service costs.	Y
1783	Our marketing plan is to use Sales Representatives to engage doctors on the appropriate use and benefits of Roxybond. In pricing this NDC, we considered cost of goods to manufacture, research investment costs, medical and patient service costs.	Y

WAC on the date the Product was commercially available

A narrative description of the marketing and pricing plans used in the launch of the new prescription drug in the United States and internationally

Please respond with Yes or No

Yes, this should be **nonpublic**

ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR	PRIORITY REVIEW INDICATOR
3,200,000.00	N	Y
3,200,000.00	N	Y
1,600,000.00	N	Y

The estimated number of patients in the United States with a condition for which the new prescription drug may be prescribed

Indicate whether the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to approval

Indicate whether the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to approval

ACQUISITION DATE	ACQUISITION PRICE	ACQUISITION PRICE NONPUBLIC
9/16/2020	Ohemo Inc.	Y
9/16/2020	Ohemo Inc.	Y
9/16/2020	Ohemo Inc.	Y

If this field in N/A then please leave blank

If this field in N/A then please leave blank

Please respond with Yes or No

ACQUISITION PRICE COMMENT	GENERAL COMMENTS
Private Transaction	
Private Transaction	
Private Transaction	

If this field is N/A then please leave blank

